EUVIMEDEUVIMED entdecken
Crossref

Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia

Eitan Kugler, Inbar Cohen, Irina Amitai, Ron Ram, Avraham Frisch, Boaz Nachmias, Jonathan Canaani, Yakir Moshe, Baher Krayem, Shlomzion Aumann, Israel Henig, Vladimir Vainstein iD und 9 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Eitan Kugler und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Aniline Compounds, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with FLT3 ‐mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard‐of‐care for patients with R/R FLT3 ‐mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt‐ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib ( n = 19) and gilt‐ven ( n = 17) for R/R AML after intensive chemotherapy. Gilteritinib and gilt‐ven groups did not differ in terms of mCRc rates (53% and 65%, p = 0.51) and realization of allogeneic haematopoietic stem‐cell transplantation (HSCT, 47% and 35%, p = 0.5). Overall survival (OS) was comparable between groups, although a trend towards better OS was seen with gilt‐ven (12‐month OS 58.8% [95% CI 39.5%–87.6%]) versus gilteritinib (42.1% [95% CI 24.9%–71.3%] for gilteritinib). Early salvage with gilt‐ven versus any other gilteritinib‐based approach was associated with the best outcome ( p = 0.031). Combination therapy was associated with increased haematological toxicity. In summary, gilt‐ven did not improve remissions or HSCT‐realization rates in patients with R/R FLT3 ‐mutated AML as compared with gilteritinib and was associated with increased haematological toxicity. Although OS did not differ, a trend towards better survival was suggested with gilt‐ven and a survival benefit was shown for gilt‐ven approach when sequenced early for salvage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Aniline CompoundsSulfonamidesBridged Bicyclo Compounds, HeterocyclicPyrazinesMutationAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMaleFemaleAgedAdultRecurrenceHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

Fms‐related receptor tyrosine kinase 3 (FLT3) mutationacute myeloid leukaemia (AML)gilteritinibvenetoclax

Substanzen

gilteritinibfms-Like Tyrosine Kinase 3venetoclaxAniline CompoundsSulfonamidesBridged Bicyclo Compounds, HeterocyclicPyrazinesFLT3 protein, human

Autor:innen und Institutionen

  • Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Haematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
  • Institute of Haematology, Tel-Aviv Sourasky Medical Center (TLVMC), Tel-Aviv, Israel.
  • Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.

ORCID-Profile: Vladimir Vainstein, Liat Shargian, Chezi Ganzel, Yishai Ofran, Shai Shimony, Ofir Wolach

Zitieren

APA

Kugler, E., Cohen, I., Amitai, I., Ram, R., Frisch, A., Nachmias, B., Canaani, J., Moshe, Y., Krayem, B., Aumann, S., Henig, I., Vainstein, V., Shargian, L., Ganzel, C., Yeshurun, M., Levi, I., Raanani, P., Akria, L., Ofran, Y., …, & Wolach, O. (2024). Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19548

Vancouver

Kugler E, Cohen I, Amitai I, Ram R, Frisch A, Nachmias B, et al. Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19548

BibTeX
@article{Kugler2024,
  author = {Kugler, Eitan and Cohen, Inbar and Amitai, Irina and Ram, Ron and Frisch, Avraham and Nachmias, Boaz and Canaani, Jonathan and Moshe, Yakir and Krayem, Baher and Aumann, Shlomzion and Henig, Israel and Vainstein, Vladimir and Shargian, Liat and Ganzel, Chezi and Yeshurun, Moshe and Levi, Itay and Raanani, Pia and Akria, Luiza and Ofran, Yishai and Shimony, Shai and Wolach, Ofir},
  title = {Gilteritinib with or without venetoclax for relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19548}
}
Kostenlos starten →